Table 3.
Correlation between serum RASSF1A gene promoter methylation status and clinicopathologic parameters in gastric and colorectal adenocarcinoma patients
| Clinicopathologic parameters |
Gastric cancer |
Colorectal cancer |
|||||
|
RASSF1A promoter status |
P value |
RASSF1A promoter status |
P value | ||||
| M | U | M | U | ||||
| Sex | Male | 9 | 20 | 0.58071 | 7 | 17 | 0.96491 |
| Female | 7 | 11 | 6 | 15 | |||
| Age (yr) | ≤ 60 | 8 | 13 | 0.59821 | 8 | 23 | 0.50242 |
| > 60 | 8 | 18 | 5 | 9 | |||
| Differentiation grade | G1/Broders’ I | 0 | 2 | 0.22801 | 1 | 3 | 0.98301 |
| G2/Broders’ II | 6 | 17 | 10 | 24 | |||
| G3/Broders’ III & IV | 10 | 12 | 2 | 5 | |||
| Surgical resection | Yes | 7 | 20 | 0.22031 | 5 | 10 | 0.73252 |
| No | 9 | 11 | 8 | 22 | |||
| Distant metastasis | Yes | 7 | 5 | 0.07462 | 5 | 5 | 0.12372 |
| No | 9 | 26 | 8 | 27 | |||
| Serum CEA | Elevated | 7 | 7 | 0.23652 | 6 | 7 | 0.12322 |
| Normal | 3 | 10 | 3 | 14 | |||
1
Chi-square test;
2
Fisher’s exact test. CEA: Carcinoembryonic antigen; M: Methylated; U: Unmethylated.